Vanda Pharmaceuticals | VNDA - Ativo Circulante





Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Akebia Therapeutics USD 252.96M 5.38M 2025-12
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.17B 223.75M 2025-12
AstraZeneca USD 29.61B 890M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Heron Therapeutics USD 238.07M 8.67M 2025-12
Insmed USD 1.79B 137.6M 2025-12
J&J USD 59.17B 3.55B 2026-03
Lexicon Pharmaceuticals USD 101.9M 20.63M 2025-12
Ligand Pharmaceuticals USD 832.27M 78.35M 2025-12
Merck USD 35.02B 8.5B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Moderna USD 5.77B 774M 2026-03
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.27B 266.14M 2025-12
Puma Biotechnology USD 143.58M 7M 2025-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.16B 789M 2026-03
Takeda JPY 3.12T 195.82B 2025-12
Teva Pharmaceutical Industries USD 13.71B 236M 2026-03
Ultragenyx Pharmaceutical USD 951M 307.79M 2025-12
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Veracyte USD 488.38M 39.15M 2025-12